College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, China.
FEBS Open Bio. 2024 Jun;14(6):1011-1027. doi: 10.1002/2211-5463.13800. Epub 2024 Apr 11.
Tumor immunotherapy can be a suitable cancer treatment option in certain instances. Here we investigated the potential immunomodulatory effect of oral glycyrrhiza polysaccharides (GCP) on the antitumor function of γδT cells in intestinal epithelial cells in mice. We found that GCP can inhibit tumor growth and was involved in the regulation of systemic immunosuppression. GCP administration also promoted the differentiation of gut epithelia γδT cells into IFN-γ-producing subtype through regulation of local cytokines in gut mucosa. GCP administration increased local cytokine levels through gut microbiota and the gut mucosa Toll-like receptors / nuclear factor kappa-B pathway. Taken together, our results suggest that GCP might be a suitable candidate for tumor immunotherapy, although further clinical research, including clinical trials, are required to validate these results.
肿瘤免疫疗法在某些情况下可以作为一种合适的癌症治疗选择。在这里,我们研究了口服甘草酸多糖(GCP)对小鼠肠道上皮细胞中γδT 细胞抗肿瘤功能的潜在免疫调节作用。我们发现 GCP 可以抑制肿瘤生长,并参与调节全身免疫抑制。GCP 给药还通过调节肠道黏膜局部细胞因子促进肠道上皮 γδT 细胞向 IFN-γ 产生亚型分化。GCP 通过肠道菌群和肠道黏膜 Toll 样受体/核因子 kappa-B 途径增加局部细胞因子水平。总之,我们的结果表明 GCP 可能是肿瘤免疫治疗的合适候选药物,但需要进一步的临床研究,包括临床试验来验证这些结果。